Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

HIV Infections 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Cachexia 1Acquired Immunodeficiency Syndrome 1

Interventions

Zidovudine 6tecogalan 4Vincristine 4Interferon alpha-2 4Doxorubicin 4Bleomycin 4sargramostim 3pomalidomide 2interferon alfa-n1 2liposomal doxorubicin 1Zalcitabine 1Tumor Necrosis Factor-alpha 1Sorafenib 1Pentoxifylline 1O-(Chloroacetylcarbamoyl)fumagillol 1Nivolumab 1Muromonab-CD3 1Methotrexate 1Leucovorin 1Isotretinoin 1Interleukin-4 1Interleukin-2 1Interferon beta-1b 1Etoposide 1Didanosine 1Dexamethasone 1Cytarabine 1Cyclophosphamide 1Cidofovir 14,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Acquired Immunodeficiency Syndrome × Pentoxifylline × Clear all
NCT00000646 2021-11-02

Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 1 Completed
54 enrolled

Acquired Immunodeficiency Syndrome, Cachexia, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡